2025 China Antidepressants Revenue Opportunities Report
Description
The 2025 China Antidepressants Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antidepressants by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in China's antidepressants market, especially in escitalopram (a leading SSRI), are H. Lundbeck A/S, Sichuan Kelun Pharmaceutical Co., Ltd., Jewim Pharmaceutical (Shandong) Co., Ltd., and Hunan Dongting Pharmaceutical Co., Ltd. H. Lundbeck is a Danish multinational known for its Lexapro® brand escitalopram, which holds a significant share in China. Sichuan Kelun, Jewim, and Hunan Dongting are major Chinese pharmaceutical firms producing generic or branded escitalopram formulations, contributing to the expanding antidepressant market driven by increasing depression prevalence and improved treatment awareness in China.
On the global scale, major players with a strong presence in China include Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., and Merck & Co. These companies focus on innovating and marketing diverse antidepressant therapies beyond SSRIs to cover broader CNS disorders. The antidepressant market in China is growing, with SSRIs like escitalopram as preferred treatments, despite their high cost compared to other antidepressants. Domestic companies also play an essential role in market growth alongside multinational firms, responding to rising mental health needs amid urbanization and societal changes.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antidepressants by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in China's antidepressants market, especially in escitalopram (a leading SSRI), are H. Lundbeck A/S, Sichuan Kelun Pharmaceutical Co., Ltd., Jewim Pharmaceutical (Shandong) Co., Ltd., and Hunan Dongting Pharmaceutical Co., Ltd. H. Lundbeck is a Danish multinational known for its Lexapro® brand escitalopram, which holds a significant share in China. Sichuan Kelun, Jewim, and Hunan Dongting are major Chinese pharmaceutical firms producing generic or branded escitalopram formulations, contributing to the expanding antidepressant market driven by increasing depression prevalence and improved treatment awareness in China.
On the global scale, major players with a strong presence in China include Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., and Merck & Co. These companies focus on innovating and marketing diverse antidepressant therapies beyond SSRIs to cover broader CNS disorders. The antidepressant market in China is growing, with SSRIs like escitalopram as preferred treatments, despite their high cost compared to other antidepressants. Domestic companies also play an essential role in market growth alongside multinational firms, responding to rising mental health needs amid urbanization and societal changes.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
